CIDO SpA-Oncology (Site 0302)

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Prostate cancer2 trials

Phase

• Phase 1/21 trial
• Phase 31 trial

Status

• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Merck Sharp & Dohme LLC2 trials

Running trials

• Active, not recruiting

  Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

  NCT06353386· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

  Contact: Study Coordinator

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer1 recruiting